天眼查工商信息显示，9月15日，广东战新产业创业投资基金合伙企业（有限合伙）成立，执行事务合 伙人为广东能源集团产业投资私募基金管理有限公司、工银资本管理有限公司，出资额30亿人民币，经 营范围为以私募基金从事股权投资、投资管理、资产管理等活动。合伙人信息显示，该基金由广东新型 储能产业投资基金合伙企业（有限合伙）、工银金融资产投资有限公司、广东储能产业发展有限公司、 工银资本管理有限公司、广东能源集团产业投资私募基金管理有限公司共同出资。 ...

Core Viewpoint - The company New Industry (300832) has received a medical device registration certificate from the Guangdong Provincial Drug Administration for a cardiac-type fatty acid binding protein assay kit, which is intended for the auxiliary diagnosis of acute myocardial infarction [1] Group 1 - The product is named "Cardiac-type Fatty Acid Binding Protein Assay Kit (Latex Immunoturbidimetric Method)" [1] - The assay kit is used for the quantitative measurement of cardiac-type fatty acid binding protein levels in human serum or plasma [1] - The clinical application of the product is specifically for assisting in the diagnosis of acute myocardial infarction [1]

格隆汇9月16日丨新产业(300832.SZ)公布，收到了广东省药品监督管理局颁发的1项《医疗器械注册 证》，产品名称：心脏型脂肪酸结合蛋白测定试剂盒（胶乳免疫比浊法）。截至目前，公司已先后取得 73项生化试剂《医疗器械注册证》（共107个注册证）。以上试剂及仪器新产品医疗器械注册证的取 得，丰富了公司生化检测产品中"心血管及心肌标志物"项目类别，将对公司发展具有正面影响，但对近 期的生产经营和业绩不会产生重大影响，敬请投资者给予关注并注意投资风险。 ...

每经头条（nbdtoutiao）——海拔4306米现"秦始皇密令"，获官方"身份认定"！古文字学家刘钊：秦人 寻仙采药足迹确至青藏高原 （记者 张明双） 每经AI快讯，新产业（SZ 300832，收盘价：68.88元）9月16日晚间发布公告称，近日，深圳市新产业 生物医学工程股份有限公司收到了广东省药品监督管理局颁发的1项《医疗器械注册证》。产品名称 为"心脏型脂肪酸结合蛋白测定试剂盒"。 2025年1至6月份，新产业的营业收入构成为：体外诊断占比99.84%，其他业务占比0.16%。 截至发稿，新产业市值为541亿元。 ...

深圳市新产业生物医学工程股份有限公司 证券代码：300832 证券简称：新产业 公告编号：2025-072 | 产品名称 | | 注册 分类 | 注册证编号 | | | 注册证有效期 | | | 适用范围 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 心脏型脂 | 肪酸 | | | | | | | | 本试剂盒用于体外定量测定 人血清或血浆中心脏型脂肪 | | 结合蛋白 | 测定 | | 粤械注准 | 2025 | 年 | 09 | 月 12 | 日至 | | | | | Ⅱ类 | | | | | | | 酸结合蛋白的含量。临床上 | | 试剂盒（胶乳免 | | | 20252401250 | 2030 | 年 | 09 | 月 11 | 日 | | | | | | | | | | | | 用于急性心肌梗死的辅助诊 | | 疫比浊法） | | | | | | | | | 断。 | 一、获证产品的具体情况 急性心肌梗死（AMI）是由于冠状动脉急性阻塞导致相应心肌区域供血不足， 使心肌坏死的影响生命的疾病。全球范围内，AMI 发 ...

Core Viewpoint - Local state-owned enterprises in Shandong are increasingly selling real estate assets, with over a hundred properties listed for transfer, totaling several million yuan in value [1][5]. Group 1: Property Listings and Sales - Yantai Yeda International Talent Group is selling several properties, including residential units and parking spaces, with total listing prices reaching approximately 164.68 million yuan for eight units in Lecheng Community [2][3]. - The properties in the listings require a one-time payment, with a deposit of over 500,000 yuan needed to participate in the purchase [2]. - Other state-owned enterprises, such as Yantai Yeda Urban Development Group, are also listing properties, with residential units priced around 700,000 yuan each, and some units still under lease [2][3]. Group 2: Market Context and Motivations - The trend of state-owned enterprises selling properties is driven by liquidity pressures due to a downturn in the real estate market and increased debt repayment obligations [5][6]. - Many of the properties being sold are older assets, such as government-allocated storefronts or low-yield rental properties, which have high holding costs [6]. - The sales are seen as a strategy to quickly recover cash for debt repayment or to fund infrastructure and public welfare projects [5][6]. Group 3: Transaction Process and Considerations - The properties listed for sale have clear ownership and are subject to a thorough verification process before being publicly listed [1][5]. - Buyers are advised to conduct due diligence, particularly regarding tax implications and existing lease agreements, as some properties may come with conditions [1][6]. - The sales process involves a formal contract signed between the buyer and seller, with oversight from the property trading center to ensure compliance [5].

Core Viewpoint - The company has recently received a patent certificate from the National Intellectual Property Administration for an invention titled "18-OXOF antibody or its antigen-binding fragment" [2] Group 1 - The patent certificate signifies a potential advancement in the company's research and development efforts [2] - The invention may enhance the company's product offerings in the biotechnology sector [2] - This development could position the company favorably in the competitive landscape of antibody-based therapies [2]

证券代码：300832 证券简称：新产业 公告编号：2025-071 深圳市新产业生物医学工程股份有限公司 关于公司获得发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）于近日收到 国家知识产权局颁发的1项《发明专利证书》，现将本次取得的发明专利具体情 况公告如下： 发明名称：18-OXOF抗体或其抗原结合片段 专利申请日：2025年06月18日 授权公告日：2025年09月09日 上述专利保护技术为公司自主研发，应用于公司免疫检测项目18-氧皮质醇 （18-OXOF），18-OXOF为公司重要的小分子夹心法项目，是原发性醛固酮增 多症（原醛症）分型诊断的关键标志物之一，进一步助力高血压早诊早筛。本发 明提供了一种的抗体，该抗体对18-OXOF具有较好的亲和力和特异性，利用该抗 体检测18-OXOF，可以显著提高检测结果的准确性和灵敏度。 本次取得的发明专利不会对公司目前的经营状况产生重大影响，但有利于完 善公司知识产权体系，进一步提升公司软实力。 特此公告。 深圳市新产业生物医学工程股 ...

Overall Industry Summary - In 2024, 453 pharmaceutical companies achieved revenue of 2.46 trillion yuan, a year-on-year decline of 0.55%, and a net profit of 148.65 billion yuan, down 8.8% [1] - In the first half of 2025, revenue is expected to be 1.22 trillion yuan, a decrease of 2.5%, with a net profit of 102 billion yuan, down 2.1% [1] Innovative Drugs - In the first half of 2025, innovative drug companies achieved revenue of 26.964 billion yuan, a year-on-year increase of 11.78%, indicating strong momentum [1] - Domestic innovative drug companies are transitioning from R&D to commercialization, marking a turning point towards profitability [1] - Outbound licensing has become a second growth curve for biotech companies, providing sustainable funding for R&D through high upfront payments [1] Chemical Drugs - In the first half of 2025, chemical drug companies reported revenue of 198.057 billion yuan, a decline of 3.83%, with a net profit of 22.139 billion yuan, down 0.11% [1] - Traditional generic-to-innovative drug companies performed well, with notable examples including Hengrui Medicine and Haizheng [1] - The chemical drug sector is expected to further differentiate, with innovative companies likely to benefit in the medium to long term [1] Medical Devices - In the first half of 2025, medical device companies achieved revenue of 106.82 billion yuan, down 5.32%, and a net profit of 17.58 billion yuan, down 18.07% [2] - The performance of high-value consumables is driven by factors such as inventory levels and policy impacts, suggesting potential turning points and innovation opportunities [2] Biological Products - Blood products in 2024 generated revenue of 24.18 billion yuan, down 1.4%, with a net profit of 6.23 billion yuan, up 14.47% [2] - Vaccine companies faced significant declines, with 2024 revenue of 40.77 billion yuan, down 45.3%, and a net profit of 3.2 billion yuan, down 72% [2] Traditional Chinese Medicine - In the first half of 2025, traditional Chinese medicine companies reported revenue of 174.376 billion yuan, down 4.57%, with a net profit of 22.479 billion yuan, up 0.70% [3] - The sector is under pressure due to stricter regulations and weak consumer demand, but there are opportunities for leading OTC brands and innovative companies [3] Raw Materials - In the first half of 2025, raw material drug companies achieved revenue of 47.86 billion yuan, down 2.90%, with a net profit of 8.1 billion yuan, up 20.61% [3] - High-performing segments include peptides and vitamin E/A, with companies like Nuotai Bio and New Hecheng showing strong results [3] Pharmaceutical Commerce - In the first half of 2025, pharmaceutical commerce companies reported revenue of 517.86 billion yuan, flat year-on-year, with a net profit of 12.09 billion yuan, up 7.6% [4] - Offline pharmacies achieved revenue of 57.77 billion yuan, up 0.1%, and a net profit of 2.55 billion yuan, up 0.9% [4] Medical Services - In the first half of 2025, medical service companies reported revenue of 36.36 billion yuan, down 4.93%, with a net profit of 2.352 billion yuan, down 11.17% [5] - The performance of eye care companies showed growth, with revenue of 16.102 billion yuan, up 6.75% [5] CXO & Research Services - In the first half of 2025, the CXO and research services sector achieved revenue of 50.64 billion yuan, up 13.05%, with a net profit of 11.91 billion yuan, up 60.6% [6] - The sector continues to show improvement, with leading CXO companies demonstrating strong resilience and growth [6]

Group 1 - The pharmaceutical sector showed volatility with the Medical Innovation ETF (516820.SH) initially dropping but later rising over 2.7%, narrowing its decline to 0.97% [1] - Among the constituent stocks, Haikang (002653) led with a gain of 2.42%, while Hengrui Medicine (600276) experienced the largest decline at 3.30% [1] - According to Founder Securities, the strong mainline attribute of innovative drugs remains unchanged, with September potentially marking a new wave for innovative drugs due to several factors including the clearing of mid-year reports and upcoming key academic conferences [1] Group 2 - The Medical Innovation ETF has seen continuous net inflows over the past three days, with a peak single-day net inflow of 12.87 million yuan, totaling 25.11 million yuan [1] - Leverage funds are actively positioning themselves, with the latest financing buy amounting to 5.53 million yuan and a financing balance of 45.45 million yuan [1] - Institutions remain confident in quality innovation and the innovation industry chain, viewing any external disturbances as buying opportunities [2]